Antagonism of P2Y12reduces physiological thromboxane levels

التفاصيل البيبلوغرافية
العنوان: Antagonism of P2Y12reduces physiological thromboxane levels
المؤلفون: Alan T. Nurden, Theodore Kent Gartner, Jianguo Jin, Alexander Georgakis, Yoshiaki Tomiyama, Paquita Nurden, Kamala Bhavaraju, Satya P. Kunapuli
المصدر: Platelets. 21:604-609
بيانات النشر: Informa UK Limited, 2010.
سنة النشر: 2010
مصطلحات موضوعية: medicine.medical_specialty, Aspirin, Prasugrel, biology, Thromboxane, business.industry, Hematology, General Medicine, Pharmacology, Clopidogrel, Endocrinology, P2Y12, Internal medicine, medicine, biology.protein, Platelet, Thromboxane-A synthase, business, Ex vivo, medicine.drug
الوصف: Antiplatelet therapy for the management of patients with cardiovascular risks often includes a combination therapy of aspirin and clopidogrel, acting through inhibition of thromboxane generation and blockade of Gi-coupled P2Y12 receptor, respectively. We hypothesized that ADP acting through P2Y12 regulates physiological thromboxane levels. The serum thromboxane levels in mice (n = 3) dosed with clopidogrel and prasugrel were decreased by 83.1 ± 5.3% and 94.26 ± 1.75% respectively compared to untreated mice. Pre-treatment of human blood (n = 3) ex vivo with active metabolites of clopidogrel or prasugrel led to a reduction in thromboxane levels to 16.3 ± 3.2% and 4.9 ± 0.8% respectively, compared to untreated human serum. We also evaluated serum thromboxane levels in P2Y receptor null mice (n = 4). Whereas serum thromboxane levels in P2Y1 null mice were similar to those in wild type littermates, those in the P2Y12 null mice were inhibited by 83.15 ± 3.8%. Finally, in a pilot study, serum thromboxane levels ...
تدمد: 1369-1635
0953-7104
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::5c518389d9919ee7a6ac5ffb2a3a23a2Test
https://doi.org/10.3109/09537104.2010.511684Test
رقم الانضمام: edsair.doi...........5c518389d9919ee7a6ac5ffb2a3a23a2
قاعدة البيانات: OpenAIRE